FibroGen (FGEN) Misses Q2 EPS by 100c

FibroGen (NASDAQ: FGEN) reported Q2 EPS of ($1.45), $1.00 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $24.4 million versus the consensus estimate of $71.38 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Credo Technology shares rise on analyst support and conference comments
• BMO Capital Reiterates Market Perform Rating on Axalta Coating Systems (AXTA)